Nf Κb Signaling In Neuroinflammation represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) Signaling is a central pathway regulating inflammatory responses in the central nervous system. Chronic NF-κB activation drives neuroinflammation, a hallmark of virtually all neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and frontotemporal dementia (FTD). Understanding NF-κB's role provides critical insights into disease mechanisms and therapeutic targets.
The NF-κB family consists of five related transcription factors:
| Protein | Heterodimers | Primary Location | Function |
|---|---|---|---|
| p50 (NF-κB1) | p50/p65 (canonical) | Cytoplasm | Inflammatory genes |
| p52 (NF-κB2) | p52/RelB (non-canonical) | Nucleus | Developmental genes |
| RelA (p65) | p50/p65 | Cytoplasm | Pro-inflammatory |
| RelB | p52/RelB | Nucleus | Adaptive immunity |
| c-Rel | c-Rel/p50 | Cytoplasm | Lymphocyte activation |
Stimulus (TNF-α, IL-1β, Aβ, LPS)
↓
Pattern Recognition Receptor (TLR, NLR)
↓
MyD88/TRIF adaptor proteins
↓
IKK complex activation (IKKα, IKKβ, IKKγ)
↓
IκBα phosphorylation and ubiquitination
↓
IκBα degradation by proteasome
↓
p65/p50 translocation to nucleus
↓
Gene transcription
Alternative activation through:
This pathway uses:
Aβ-Driven Inflammation
Neuronal NF-κB
Therapeutic Implications
Microglial Activation
Neuronal Death
Genetic Links
SOD1 Mutations
Inflammatory Milieu
| Compound | Mechanism | Status |
|---|---|---|
| BAY 11-7082 | IKK inhibitor | Preclinical |
| Wedelolactone | IKK inhibitor | Research |
| Aspirin | IKKβ inhibition | Clinical |
| Sulforaphane | Nrf2-NF-κB crosstalk | Investigational |
The study of Nf Κb Signaling In Neuroinflammation has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Glass, C.K., et al. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell, 140(6): 918-934.
Heneka, M.T., et al. (2015). Neuroinflammation in Alzheimer's disease. Lancet Neurol., 14(4): 388-405.
Papa, S., et al. (2016). NF-κB, p53, and mitochondrial dysfunction in Alzheimer's disease. Adv. Exp. Med. Biol., 878: 103-114.
Ghosh, S., & Hayden, M.S. (2012). Celebrating 25 years of NF-κB. Cell, 148(1-2): 16-18.
Zhang, G., et al. (2010). Synergistic dopaminergic neurodegeneration: Role of NF-κB. Neurobiol. Aging, 31(9): 1626-1634.
Frakes, M.S., et al. (2014). Microglia and the NF-κB signaling pathway in ALS. Neurodegener. Dis., 13(2-3): 166-172.
Kaltschmidt, B., & Kaltschmidt, C. (2009). NF-κB in the nervous system. Cold Spring Harb. Perspect. Biol., 1(3): a001271.
Mattson, M.P., & Meffert, M.K. (2006). Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death Differ., 13(5): 852-860.
Dresselhaus, E.C., & Meffert, M.K. (2019). Cellular specificity of NF-κB function in the nervous system. Front. Immunol., 10: 1043.
Yu, H., et al. (2020). NF-κB and its link with neurodegeneration. Neurochem. Int., 141: 104857.
[[mechanisms/neuroinflammation-microglia-pathway|Microglia Neuroinflammation Pathway]]
[[mechanisms/nlrp3-inflammasome-pathway|NLRP3 Inflammasome Pathway]]
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%